Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021241 citationsJournal Articlehybrid Open Access

Authors

Salma K. Jabbour · Rutgers, The State University of New Jersey

Ki Hyeong Lee · Chungbuk National University Hospital

Nikolaj Frost · Humboldt-Universität zu Berlin

В. В. Бредер · Russian Cancer Research Center NN Blokhin

Dariusz M. Kowalski · The Maria Sklodowska-Curie National Research Institute of Oncology

Theodore Pollock · Northeastern State University

E. Levchenko

Abstract

The findings of this phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: JAMA Oncology

Volume 7, Issue 9, pp. 1351-1351

DOI: 10.1001/jamaoncol.2021.2301

Field-Weighted Citation Impact: 26.13